Is Aura Biosciences, Inc. (AURA) Halal?

NASDAQ Healthcare United States $398M
✗ NOT HALAL
Confidence: 83/100
Aura Biosciences, Inc. (AURA) is Not Halal under AAOIFI Standard 21. While the debt ratio of 5.3% is acceptable, the cash and interest-bearing securities ratio of 42.5% exceeds the 30% threshold. Aura Biosciences, Inc. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 5.3%
/ 30%
42.5%
/ 30%
0.0%
/ 30%
N/A ✗ NOT HALAL
DJIM 5.3%
/ 33%
42.5%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
MSCI 10.3%
/ 33%
82.8%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
S&P 5.3%
/ 33%
42.5%
/ 33%
0.0%
/ 33%
N/A ✗ NOT HALAL
FTSE 10.3%
/ 33%
82.8%
/ 33%
0.0%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-1.91
P/B Ratio
2.5
EV/EBITDA
-2.3
EV: $254M
Revenue
$0
Beta
0.4
Low volatility
Current Ratio
9.0

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -64.3%
Return on Assets (ROA) -35.8%

Cash Flow & Balance Sheet

Operating Cash Flow-$80M
Free Cash Flow-$81M
Total Debt$19M
Debt-to-Equity11.3
Current Ratio9.0
Total Assets$183M

Price & Trading

Last Close$6.44
50-Day MA$5.81
200-Day MA$6.09
Avg Volume226K
Beta0.4
52-Week Range
$4.34
$7.48

About Aura Biosciences, Inc. (AURA)

CEO
Dr. Elisabet de los Pinos Ph.D.
Employees
106
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$398M
Currency
USD

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmette–guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Aura Biosciences, Inc. (AURA) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Aura Biosciences, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Aura Biosciences, Inc.'s debt ratio?

Aura Biosciences, Inc.'s debt ratio is 5.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 10.3%.

What are Aura Biosciences, Inc.'s key financial metrics?

Aura Biosciences, Inc. has a market capitalization of $398M. Return on equity stands at -64.3%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.